Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$236.72
$254.83
$186.05
▼
$282.15
$14.77B0.35730,003 shs1.56 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.61
$79.31
$48.78
▼
$93.42
$13.02B0.972.07 million shs4.10 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$7.31
$7.75
$6.96
▼
$10.23
$4.98B0.67378,174 shs367,746 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.85
$14.71
$12.07
▼
$29.23
$14.24B-1.246.28 million shs13.06 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-10.17%-6.54%+3.82%+19.75%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-8.05%-18.27%-3.35%+27.19%
Grifols, S.A. stock logo
GRFS
Grifols
0.00%-3.18%-8.63%+0.41%-24.95%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%+1.71%+35.64%+25.00%-5.51%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$236.72
$254.83
$186.05
▼
$282.15
$14.77B0.35730,003 shs1.56 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.61
$79.31
$48.78
▼
$93.42
$13.02B0.972.07 million shs4.10 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$7.31
$7.75
$6.96
▼
$10.23
$4.98B0.67378,174 shs367,746 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.85
$14.71
$12.07
▼
$29.23
$14.24B-1.246.28 million shs13.06 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-10.17%-6.54%+3.82%+19.75%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-8.05%-18.27%-3.35%+27.19%
Grifols, S.A. stock logo
GRFS
Grifols
0.00%-3.18%-8.63%+0.41%-24.95%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%+1.71%+35.64%+25.00%-5.51%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7531.27% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$102.6154.05% Upside
Grifols, S.A. stock logo
GRFS
Grifols
1.67
Reduce$10.0036.80% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.47
Hold$25.9145.14% Upside

Current Analyst Ratings Breakdown

Latest GRFS, ASND, SMMT, and BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$344.00
9/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$287.00
9/10/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$344.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/10/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/9/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone logo
Summit Redstone
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
9/8/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$33.00
9/3/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M18.13N/AN/A($2.97) per share-79.70
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$713.07M18.26N/AN/A($10.77) per share-6.18
Grifols, S.A. stock logo
GRFS
Grifols
$8.51B0.58$1.42 per share5.16$12.64 per share0.58
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8918.3626.69N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Grifols, S.A. stock logo
GRFS
Grifols
$454.82M$0.1938.475.460.275.54%6.21%2.39%11/10/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest GRFS, ASND, SMMT, and BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.28N/AN/AN/A$0.07 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
$0.091.23%N/A47.37%N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Grifols, S.A. stock logo
GRFS
Grifols
1.10
2.37
0.81
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Grifols, S.A. stock logo
GRFS
Grifols
N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
Grifols, S.A. stock logo
GRFS
Grifols
25,247680.58 million679.28 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265797.75 million131.63 millionOptionable

Recent News About These Companies

Engineers Gate Manager LP Makes New Investment in Summit Therapeutics PLC $SMMT
September 20 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-engineers-gate-manager-lp-makes-new-investment-in-summit-therapeutics-plc-smmt-2026-09-20/
Summit Therapeutics: It's Okay Not To Have An Answer
September 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947471-summit-therapeutics-its-okay-not-to-have-an-answer
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)
September 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SMMT/pressreleases/4613211/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-and-azenta-azta/
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 7% - Should You Sell?
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-stock-price-down-7-should-you-sell-2026-09-15/
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
September 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260915307340/en/Updated-HARMONi-Data-Presented-at-WCLC-2026-Demonstrate-Consistent-Overall-Survival-Results-with-Ivonescimab-Plus-Chemotherapy-in-Western-and-Asian-Patients/
Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer
September 13, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Ivonescimab+cuts+death+risk+27%25+vs.+pembrolizumab+in+lung+cancer/27054356.html
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso ...
September 13, 2026  |  streetinsider.comhttps://www.streetinsider.com/Business+Wire/Ivonescimab+Monotherapy+Demonstrates+a+Statistically+Significant+%26amp%3B+Clinically+Meaningful+Benefit+Compared+to+Pembrolizumab+Monotherapy+in+PD-L1-Positive+Advanced+NSCLC+in+Akeso%E2%80%99s+HARMONi-2+Study/27054259.html
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
September 13, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/summit-s-ivonescimab-cuts-death-risk-by-27-versus-keytruda-in-lung-cancer-trial/ar-AA2c8ugF
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
September 13, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9078710/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pdl1positive-advanced-nsclc-in-akesos-harmoni2-study-condu
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China
September 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260913549808/en/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pd-l1-positive-advanced-nsclc-in-akeso%e2%80%99s-harmoni-2-study-conducted-in-china/
Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-shares-of-120560-summit-therapeutics-plc-smmt-2026-09-12/
Summit Therapeutics PLC (SMMT)
September 10, 2026  |  fr.investing.comhttps://fr.investing.com/equities/summit-therapeutics-plc-news
Summit Therapeutics Shares Rise After Upgrade From Jefferies
September 9, 2026  |  marketscreener.comM
Summit Therapeutics shares gain after Jefferies upgrades stock to buy
September 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/summit-therapeutics-shares-gain-after-jefferies-upgrades-stock-to-buy/ar-AA2bSSP1
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Time to Buy?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-time-to-buy-2026-09-09/
Summit Therapeutics PLC $SMMT Shares Bought by Wellington Management Group LLP
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-summit-therapeutics-plc-smmt-shares-bought-by-wellington-management-group-llp-2026-09-09/
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
September 8, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/summit-smmt-says-akeso-reported-a-harmoni-2-overall-survival-benefit-against-pembrolizumab-1827424/
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
September 7, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/summit-therapeutics-smmt-soars-28-on-ivonescimab-progress-1829526/
Seven Fleet Capital Management LP Acquires Shares of 73,300 Summit Therapeutics PLC $SMMT
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-acquires-shares-of-73300-summit-therapeutics-plc-smmt-2026-09-05/
Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-takes-628-million-position-in-summit-therapeutics-plc-smmt-2026-09-05/
Summit Therapeutics (NASDAQ:SMMT) Raised to Hold at Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-summit-therapeutics-nasdaq-smmt-raised-to-hold-at-wall-street-zen-2026-09-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$236.72 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$238.46 +1.74 (+0.74%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$66.61 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$66.64 +0.03 (+0.05%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Grifols stock logo

Grifols NASDAQ:GRFS

$7.31 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$7.32 +0.01 (+0.08%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$17.85 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$18.49 +0.64 (+3.58%)
As of 06:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas